anmelden
OMX Copenhagen 20
1.617,31
PKT
-3,75
PKT
-0,23
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 22.05.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 22.05.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 08.05.23 | A.P. Moeller - Maersk A-S (B) Neutral | UBS AG | |
| 05.05.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 05.05.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.05.23 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 05.05.23 | Novo Nordisk Outperform | Credit Suisse Group | |
| 04.05.23 | Novo Nordisk Sell | UBS AG | |
| 04.05.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 28.04.23 | Novo Nordisk Sell | UBS AG | |
| 27.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 20.04.23 | Novo Nordisk Overweight | Barclays Capital | |
| 18.04.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 18.04.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 14.04.23 | Novo Nordisk Sell | UBS AG | |
| 14.04.23 | Novo Nordisk Overweight | Barclays Capital | |
| 13.04.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 13.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 13.04.23 | Novo Nordisk Outperform | Credit Suisse Group | |
| 12.04.23 | Novo Nordisk Overweight | Barclays Capital | |
| 11.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 06.04.23 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 03.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 25.03.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 23.03.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 22.03.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 14.03.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 09.03.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 22.02.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 17.02.23 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 13.02.23 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.02.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 02.02.23 | Novo Nordisk Neutral | Credit Suisse Group | |
| 02.02.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 01.02.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 01.02.23 | Novo Nordisk Sell | UBS AG | |
| 01.02.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 25.01.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 25.01.23 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.01.23 | Novo Nordisk Overweight | Barclays Capital |
